Taiho Pharmaceutical to acquire Araris Biotech for $400m
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, will acquire Araris Biotech for $400 million upfront, with potential milestone payments reaching up to $740 million. The acquisition, expected to close in the first half of 2025, will bolster Taiho's biologics research and development capabilities. Araris, founded in 2019, focuses on ADC technology, which selectively delivers cytotoxic drugs to cancer cells. Taiho plans to leverage Araris' AraLinQ™ ADC linker platform to expand its oncology portfolio, complementing its existing expertise in small-molecule drugs. The acquisition is expected to enhance Taiho's drug discovery capabilities, combining small molecules and ADCs, for continued expansion of its oncology portfolio.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when Otsuka Holdings publishes news
Free account required • Unsubscribe anytime